Insights

Gathering insights about LISA…

Similar companies to LISA

LISA Tech Stack

LISA uses 8 technology products and services including AppNexus, Google AdSense, cdnjs, and more. Explore LISA's tech stack below.

AppNexus
Advertising
Google AdSense
Advertising
cdnjs
Content Delivery Network
HubSpot Cookie Policy Banner
Cookie Compliance
Element UI
Javascript Frameworks
jQuery
Javascript Libraries
Lightbox
Javascript Libraries
Slick
Javascript Libraries

Media & News

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript
Lisata Therapeutics, Inc. ( LSTA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - Executive VP of R&D and Chief Medical Officer Conference Call Participants Lander Egaña-Gorroño Robert Sassoon - Water Tower Research LLC Peter Enderlin - MAZ Capital Advisors, LLC Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, November 6, 2025.
Nov 06, 2025 | seekingalpha.com
Lisata Therapeutics advances certepetide, inks strategic alliances in Q3
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead investigational therapy, certepetide, and announcing strategic collaborations to expand its development and discovery capabilities. Certepetide, Lisata's proprietary investigational peptide, continues to be studied across multiple solid tumor types in combination with standard anti-cancer therapies.
Nov 06, 2025 | www.proactiveinvestors.com
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J.
Nov 06, 2025 | www.globenewswire.com
Lisata Therapeutics receives 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services throughout the world. The clinical-stage pharmaceutical company said the award is in recognition of its unique therapeutic approach and focused clinical development plans, designed to produce products to address the unmet medical needs of patients with advanced solid tumors.
Nov 06, 2025 | www.proactiveinvestors.com
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'
BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it is the recipient of “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
Nov 06, 2025 | www.globenewswire.com
Lisata Therapeutics reports preclinical data showing certepetide's potential to enhance cancer drug delivery
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported promising preclinical results suggesting its iRGD cyclic peptide, certepetide, could enhance the effectiveness of antibody-drug conjugates (ADCs) in cancer treatment. The data, presented by Lisata's licensing partner Catalent at the 16th Annual World ADC San Diego Conference, showed that certepetide may improve tumor penetration and broaden the distribution of cytotoxic agents within tumors.
Nov 04, 2025 | www.proactiveinvestors.com
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata's licensing partner, Catalent, Inc. (“Catalent”), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025.
Nov 04, 2025 | www.globenewswire.com

LISA's Email Address Formats

LISA uses at least 1 format(s):

LISA Email Formats	Example	Percentage
FLast@lisa.org	JDoe@lisa.org	65%
First@lisa.org	John@lisa.org	17%
F.Last@lisa.org	J.Doe@lisa.org	17%
FirstL@lisa.org	JohnD@lisa.org	1%

Frequently Asked Questions

Where is LISA's headquarters located?

LISA's main headquarters is located at Domaine en Praël, Romainmôtier, CH-1323, CH. The company has employees across 6 continents, including EuropeNorth AmericaAsia.

What is LISA's stock symbol?

LISA is a publicly traded company; the company's stock symbol is LSTA.

What is LISA's official website and social media links?

LISA's official website is lisa.org and has social profiles on LinkedIn.

What is LISA's NAICS code?

LISA's NAICS code is 813 - Religious, Grantmaking, Civic, Professional, and Similar Organizations.

How many employees does LISA have currently?

As of August 2025, LISA has approximately 237 employees across 6 continents, including EuropeNorth AmericaAsia. Key team members include Ceo: L. P.President & Chief Executive Officer: D. B.Owner: L. Z.. Explore LISA's employee directory with LeadIQ.

What industry does LISA belong to?

LISA operates in the Non-profit Organizations industry.

What technology does LISA use?

LISA's tech stack includes AppNexusGoogle AdSensecdnjsHubSpot Cookie Policy BannerElement UIjQueryLightboxSlick.

What is LISA's email format?

LISA's email format typically follows the pattern of FLast@lisa.org. Find more LISA email formats with LeadIQ.

When was LISA founded?

LISA was founded in 1990.

LISA

Q: What is LISA's official website and social media links?

LISA's official website is lisa.org. LISA has social profiles on LinkedIn.

Q: How many employees does LISA have currently?

LISA has approximately 237 employees.

Q: What technology does LISA use?

LISA's tech stack includes WooCommerce, HubSpot Cookie Policy Banner, jQuery Migrate, AppNexus, ZURB Foundation.

Non-profit OrganizationsSwitzerland201-500 Employees

Founded in 1990, LISA is the preeminent organization for the product Globalization and the Internationalization and Localization business communities. With more than 600 companies from the high-tech and other business sectors, LISA is well-known for its best practice guidelines and language technology standards for enterprise globalization. It’s the non-profit organization to join when you’re serious about doing business globally.

Company Overview

Headquarters: Domaine en Praël, Romainmôtier, CH-1323, CH
Website: lisa.org
Stock Symbol: LSTA
NAICS Code: 813 - Religious, Grantmaking, Civic, Professional, and Similar Organizations
Founded: 1990
Employees: 201-500

Media & News

Funding & Financials

$1B$10B
LISA's revenue is estimated to be in the range of $1B$10B

Funding & Financials

$1B$10B
LISA's revenue is estimated to be in the range of $1B$10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to LISA

TAUS

Gala

memoQ

Slator

CSA Research

LISA Tech Stack

Media & News

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript

Lisata Therapeutics advances certepetide, inks strategic alliances in Q3

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics receives 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

Lisata Therapeutics reports preclinical data showing certepetide's potential to enhance cancer drug delivery

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

LISA's Email Address Formats

Frequently Asked Questions

Where is LISA's headquarters located?

What is LISA's stock symbol?

What is LISA's official website and social media links?

What is LISA's NAICS code?

How many employees does LISA have currently?

What industry does LISA belong to?

What technology does LISA use?

What is LISA's email format?

When was LISA founded?

LISA

Company Overview

Media & News

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript

Lisata Therapeutics advances certepetide, inks strategic alliances in Q3

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?